bioAffinity Technologies Unveils Positive Research on Novel Diagnostic Platform at AAAAI 2026

Key Highlights from the Report

• bioAffinity Technologies (Nasdaq: BIAF; BIAFW) presented new research at the prestigious American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual Meeting in Philadelphia.
• The Company’s novel diagnostic technology successfully identified antibody drug receptors in patient sputum for two leading asthma therapies:
  • Dupilumab (used in asthma and COPD)
  • Benralizumab (asthma therapy)
• The research underscores the platform’s potential to enable more personalized treatment decisions and improved disease monitoring for asthma and COPD patients.
• The poster, “Sputum as a Diagnostic Tool for the Treatment of Asthma”, was presented by Dr. William Bauta, Chief Science Officer of bioAffinity Technologies.
• The Company’s proprietary flow cytometry and AI-driven platform aims to match patients with the most effective biologic therapies and monitor their inflammatory status over time.
• The same technology powers the Company’s commercial CyPath® Lung test, which is a noninvasive diagnostic tool for early-stage lung cancer that has shown high sensitivity (92%), specificity (87%), and accuracy (88%) for patients with small pulmonary nodules.
• Asthma and COPD affect approximately 650 million people globally, underscoring the large potential market and significant unmet medical need.

Potentially Price-Sensitive Information for Shareholders

• The Company’s research demonstrates a potential expansion of its diagnostic platform beyond lung cancer to other high-prevalence pulmonary diseases (asthma and COPD). If commercialized, this could substantially increase the addressable market and future revenue streams.
• Positive results in identifying drug-specific receptors in sputum for leading biologics like dupilumab and benralizumab may position bioAffinity as a leader in precision medicine for respiratory diseases.
• The ability to match patients to optimal therapies and monitor their response could help reduce healthcare costs and improve patient outcomes, increasing the likelihood of adoption by clinicians and payors.
• The Company’s first product, CyPath® Lung, is already marketed as a Laboratory Developed Test (LDT) by its subsidiary, Precision Pathology Laboratory Services, highlighting existing commercialization infrastructure.
• Management notes that many patients with asthma and COPD must try multiple treatments to find an effective therapy. bioAffinity’s test may reduce this trial-and-error process, providing a compelling value proposition to healthcare providers.

Detailed Overview for Investors

bioAffinity Technologies, Inc. has taken a significant step forward in the field of precision diagnostics for respiratory diseases. At the 2026 AAAAI Annual Meeting, the Company presented new research showing that its proprietary diagnostic platform can accurately identify drug-specific antibody receptors in patient sputum samples. Specifically, receptors for dupilumab and benralizumab—two leading biologic therapies for asthma and COPD—were detected using bioAffinity’s advanced flow cytometry and AI analysis.

This innovation could allow clinicians to quickly select the most effective biologic for individual patients and monitor their disease progression with a noninvasive test. Currently, many patients must experiment with several medications before finding one that works, resulting in lower quality of life and higher healthcare costs. bioAffinity’s technology could streamline this process, opening the door to truly personalized medicine for millions of asthma and COPD sufferers.

The Company’s technology is not new to the market: its CyPath® Lung test is already in commercial use and has demonstrated high accuracy in detecting early-stage lung cancer. By leveraging the same platform for asthma and COPD, bioAffinity is positioning itself to capture a larger share of the respiratory diagnostics market. With an estimated 650 million people affected globally by asthma and COPD, the market potential is enormous.

For shareholders, this news is highly significant. Positive research demonstrating the versatility and effectiveness of bioAffinity’s diagnostic platform could drive greater market interest and higher company valuation, especially if further clinical studies and regulatory approvals follow. The Company’s ongoing work to expand its product pipeline and target new indications is a key factor to watch.

Investors should also be aware of the usual risks related to medical diagnostics companies, including scientific, regulatory, and commercialization challenges. The Company has issued forward-looking statements and cautions that results may vary due to numerous factors such as data availability, regulatory approvals, competition, and general market conditions.

Contact Information

For further details, shareholders and interested parties may contact:
Julie Anne Overton
Director of Communications
[email protected]

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. All forward-looking statements are subject to risks and uncertainties. Investors should conduct their own due diligence and consult professional advisors before making investment decisions.

View bioAffinity Technologies, Inc. Historical chart here